Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Lithium and thyroid hormone augmentation
11 evidence topics · 10 sources
CANMAT guideline: lithium and triiodothyronine as second-line adjuncts
“Both medications were included in a network meta-analysis evaluating all adjunctive options. While both lithium and triiodothyronine had evidence for efficacy, the included RCTs predated 2003, had small sample sizes and involved adjunctive use with TCAs only. Lithium also requires serum level monitoring and triiodothyronine requires monitoring of thyroid levels. Hence, lithium and triiodothyronine continue to be second-line recommendations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline: lithium and liothyronine augmentation and lithium monitoring
VA/DoD guideline: lithium and liothyronine with insufficient evidence for or against
VA/DoD guideline: liothyronine remission and cautions
Third-step augmentation: lithium versus triiodothyronine
“A total of 142 adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or who were intolerant to an initial prospective treatment with citalopram and a second switch or augmentation trial were randomly assigned to augmentation with lithium (up to 900 mg/day; N=69) or with T(3) (up to 50 mug/day; N=73) for up to 14 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After a mean of 9.6 weeks (SD=5.2) of treatment, remission rates were 15.9% with lithium augmentation and 24.7% with T(3) augmentation, although the difference between treatments was not statistically significant. Lithium was more frequently associated with side effects (p=0.045), and more participants in the lithium group left treatment because of side effects (23.2% versus 9.6%; p=0.027).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lithium augmentation versus placebo: meta-analysis
“Nine trials that included 237 patients were selected. The odds ratio for response to lithium vs. placebo in all contrasts combined was 2.89 (95% CI 1.65, 5.05, z=3.72, p=0.0002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adjunctive lithium was effective with TCAs (7 contrasts) and with second generation agents (3 contrasts). Discontinuation due to adverse events was infrequent and did not differ between lithium and placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The meta-analysis is limited by the small size and number of trials and limited data for treatment resistant patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis of augmentation agents: lithium and thyroid hormones
“In order of decreasing efficacy, T3, nortriptyline, aripiprazole, brexpiprazole, quetiapine, lithium, modafinil, olanzapine (fluoxetine), cariprazine and lisdexamfetamine were statistically significant compared to placebo, with RRs ranging from 1.18 (1.03–1.37) for lisdexamfetamine to 1.90 (1.16–3.11) for T3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, we should acknowledge that remission rates were not significant compared to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, in a post-hoc sub-analysis of only three short-term studies (≤3 weeks) we found that response rates were not significant as compared to placebo (RR= 1.79; 0.48–6.67).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Thyroid hormone augmentation in unipolar treatment-resistant depression: meta-analysis
“Based on the screening of these records, we identified 10 studies that met the inclusion criteria (total number of patients = 663). The comparison of response to thyroid hormones vs. placebo resulted in an odds ratio of 1.56 (95% CI: 0.50-4.84). Similarly, the comparison of response to thyroid hormones vs. lithium resulted in an odds ratio of 1.91 (95% CI: 0.85-4.26).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“According to this review and meta-analysis, there is not sufficient evidence to support the use of adjunctive thyroid hormones for treatment-resistant unipolar depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lithium versus quetiapine augmentation over 12 months
“Participants in the quetiapine group had a significantly lower overall burden of depressive symptom severity than participants in the lithium group (area under the between-group differences curve -68·36 [95% CI -129·95 to -6·76; p=0·0296). Time to discontinuation did not significantly differ between the two groups. Quetiapine was more cost-effective than lithium.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Results of the trial suggest that quetiapine is more clinically effective than lithium as a first-line augmentation option for reducing symptoms of depression in the long-term management of treatment-resistant depression, and is probably more cost-effective than lithium.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lithium augmentation versus switch to nortriptyline in adults aged 60 years or older
“Remission occurred in 18.9% of patients in the lithium-augmentation group and 21.5% in the switch-to-nortriptyline group; rates of falling were similar in the two groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In our trial, less than 10% of the patients who switched to bupropion or had augmentation with lithium both reached and maintained the target dose and had remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote